These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. European collaboration in trials of new agents for children with cancer. Ablett S; Doz F; Morland B; Vassal G; ; Eur J Cancer; 2004 Aug; 40(12):1886-92. PubMed ID: 15288291 [TBL] [Abstract][Full Text] [Related]
25. Nanoparticle theories slowly turn into practice. Bender E Cancer Discov; 2011 Sep; 1(4):280. PubMed ID: 22586600 [No Abstract] [Full Text] [Related]
26. Newer phase II trial designs gaining ground. Benowitz S J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467 [No Abstract] [Full Text] [Related]
27. New approaches in cancer pharmacology: drug design and development. Report of a European School of Oncology Task Force. Eur J Cancer; 1992; 28A(6-7):1190-200. PubMed ID: 1627393 [No Abstract] [Full Text] [Related]
28. Cysteine cathepsin proteases as pharmacological targets in cancer. Palermo C; Joyce JA Trends Pharmacol Sci; 2008 Jan; 29(1):22-8. PubMed ID: 18037508 [TBL] [Abstract][Full Text] [Related]
29. Mechanism-based target identification and drug discovery in cancer research. Gibbs JB Science; 2000 Mar; 287(5460):1969-73. PubMed ID: 10720316 [TBL] [Abstract][Full Text] [Related]
30. Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets. Mayburd AL; Golovchikova I; Mulshine JL Bioinformatics; 2008 Feb; 24(3):389-95. PubMed ID: 17925305 [TBL] [Abstract][Full Text] [Related]
31. Targeted cancer therapy: promise and reality. Klein S; Levitzki A Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951 [TBL] [Abstract][Full Text] [Related]
32. Developing new agents for the treatment of childhood cancer. Kurmasheva R; Morton C; Houghton PJ Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407 [TBL] [Abstract][Full Text] [Related]
33. Translating cancer research by synthetic biology. Shankar S; Pillai MR Mol Biosyst; 2011 Jun; 7(6):1802-10. PubMed ID: 21437339 [TBL] [Abstract][Full Text] [Related]
34. Targets for treatment success. Simon R Nat Clin Pract Oncol; 2006 Jan; 3(1):1. PubMed ID: 16407857 [No Abstract] [Full Text] [Related]
35. Cooperation needed to optimise cancer drug development. Mayor S Lancet; 2004 Mar; 363(9414):1045. PubMed ID: 15065559 [No Abstract] [Full Text] [Related]
36. Regulation of c-Raf-1: therapeutic implications. Beeram M; Patnaik A; Rowinsky EK Clin Adv Hematol Oncol; 2003 Aug; 1(8):476-81. PubMed ID: 16258435 [TBL] [Abstract][Full Text] [Related]
37. Epigenetic opportunities and challenges in cancer. Best JD; Carey N Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050 [TBL] [Abstract][Full Text] [Related]
38. In vitro drug resistance versus chemosensitivity: two sides of different coins. Fruehauf JP; Alberts DS J Clin Oncol; 2005 May; 23(15):3641-3; author reply 3646-8. PubMed ID: 15908686 [No Abstract] [Full Text] [Related]
39. Emerging approaches in molecular profiling affecting oncology drug discovery. Friend SH Cold Spring Harb Symp Quant Biol; 2005; 70():445-8. PubMed ID: 16869782 [TBL] [Abstract][Full Text] [Related]
40. New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. Workman P Curr Cancer Drug Targets; 2001 May; 1(1):33-47. PubMed ID: 12188890 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]